CN113365636A - 用于增加组织灌注的磷酸肌醇化合物 - Google Patents

用于增加组织灌注的磷酸肌醇化合物 Download PDF

Info

Publication number
CN113365636A
CN113365636A CN202080010978.XA CN202080010978A CN113365636A CN 113365636 A CN113365636 A CN 113365636A CN 202080010978 A CN202080010978 A CN 202080010978A CN 113365636 A CN113365636 A CN 113365636A
Authority
CN
China
Prior art keywords
compound
formula
use according
group
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010978.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·F·巴西西
C·萨尔塞多·罗卡
J·佩雷罗·贝斯塔德
M·D·费勒·瑞尼斯
M·D·M·佩雷斯·费勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifu International Co ltd
Original Assignee
Sanifeld Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifeld Treatment Co ltd filed Critical Sanifeld Treatment Co ltd
Publication of CN113365636A publication Critical patent/CN113365636A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080010978.XA 2019-01-30 2020-01-30 用于增加组织灌注的磷酸肌醇化合物 Pending CN113365636A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
EP19382061.0 2019-01-30
US201962913259P 2019-10-10 2019-10-10
US62/913,259 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
CN113365636A true CN113365636A (zh) 2021-09-07

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010978.XA Pending CN113365636A (zh) 2019-01-30 2020-01-30 用于增加组织灌注的磷酸肌醇化合物

Country Status (11)

Country Link
US (2) US20220000889A1 (enExample)
EP (1) EP3917535A1 (enExample)
JP (2) JP2022521119A (enExample)
KR (1) KR20210148078A (enExample)
CN (1) CN113365636A (enExample)
AU (1) AU2020213713B2 (enExample)
BR (1) BR112021014897A2 (enExample)
CA (1) CA3130735A1 (enExample)
IL (1) IL285084A (enExample)
MX (1) MX2021008966A (enExample)
WO (1) WO2020157362A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199478A1 (en) * 2020-11-20 2022-05-27 Vifor (International) Ag Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013933A2 (en) * 1999-08-25 2001-03-01 Gmp Companies, Inc. Agents for the enhanced oxygen delivery in mammals
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
US20020142995A1 (en) * 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US20020173494A1 (en) * 2000-08-01 2002-11-21 Jean-Marie Lehn Ammonium salts of inositol hexaphosphate, and uses thereof
CN105611913A (zh) * 2013-03-15 2016-05-25 莱博若特瑞斯萨尼菲特有限公司 包含c-o-p键的衍生物在患有肾功能衰竭的患者中的用途
CN108367080A (zh) * 2015-12-11 2018-08-03 苏黎世联邦理工学院 用于病理性结晶的肌醇衍生物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
EP0632720B1 (en) 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
JP2004510687A (ja) 1999-11-02 2004-04-08 ディポメド，インコーポレイティド 胃への薬剤投与の強化のための供給モードの薬理学的誘導
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9358243B2 (en) 2011-09-29 2016-06-07 Eth Zurich Pharmaceutical compounds for use in the therapy of Clostridium difficile infection
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
CN108368137B (zh) 2015-12-11 2020-11-13 苏黎世联邦理工学院 用于艰难梭状芽胞杆菌感染的4,6-二(邻硫代磷酸盐)-肌醇-1,2,3,5-四-邻硫酸盐

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013933A2 (en) * 1999-08-25 2001-03-01 Gmp Companies, Inc. Agents for the enhanced oxygen delivery in mammals
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
US20020142995A1 (en) * 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US20020173494A1 (en) * 2000-08-01 2002-11-21 Jean-Marie Lehn Ammonium salts of inositol hexaphosphate, and uses thereof
CN105611913A (zh) * 2013-03-15 2016-05-25 莱博若特瑞斯萨尼菲特有限公司 包含c-o-p键的衍生物在患有肾功能衰竭的患者中的用途
CN108367080A (zh) * 2015-12-11 2018-08-03 苏黎世联邦理工学院 用于病理性结晶的肌醇衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. PERELLÓ等: "First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification", 《BR J CLIN PHARMACOL》, vol. 84, pages 2867 - 2876, XP055579501, DOI: 10.1111/bcp.13752 *

Also Published As

Publication number Publication date
CA3130735A1 (en) 2020-08-06
BR112021014897A2 (pt) 2021-09-28
AU2020213713A1 (en) 2021-07-22
EP3917535A1 (en) 2021-12-08
WO2020157362A1 (en) 2020-08-06
AU2020213713B2 (en) 2025-08-21
JP2024175025A (ja) 2024-12-17
JP2022521119A (ja) 2022-04-06
US20220000889A1 (en) 2022-01-06
MX2021008966A (es) 2021-11-04
IL285084A (en) 2021-09-30
US20230248749A1 (en) 2023-08-10
KR20210148078A (ko) 2021-12-07

Similar Documents

Publication Publication Date Title
US5780489A (en) Method for treating amyotrophic lateral sclerosis
JP2024175025A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
JP2016512821A (ja) ヘモグロビンの修飾のための組成物及び方法
RU2725626C2 (ru) Применение производных, содержащих связи с-о-р, у пациентов с почечной недостаточностью
US20250295676A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
Shabanov et al. Hypoxia and antihypoxants, focus on brain injury
JP2022523402A (ja) 術後認知機能障害の予防及び治療のための化合物
EP2068879A2 (en) Pyrroloquinoline quinone drugs and methods of use thereof
EP0629405A1 (en) Agent for inhibiting a decrease in bone mass in renal osteodystrophy
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
TW201717959A (zh) 用於對金屬卟啉進行微粒遞送之調配物及用途
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
US20210290642A1 (en) Ip and ip analogs dosage regimens for the treatment of ectopic calcifications
MX2007010493A (es) Compuestos que tienen propiedades reductoras de lipidos.
JP2022523053A (ja) ミトコンドリアを標的とするイソケタール／イソレブグランジンスカベンジャー
JP7752425B2 (ja) ２，２，６，６－テトラメチル－１－ピペリジニルオキシルの揮発使用による細胞死抑制と組織保護
RU2832087C1 (ru) Соединения инозитолфосфата для применения в лечении, замедлении прогрессирования или предупреждении сердечно-сосудистой кальцификации
US20230333087A1 (en) Methods for monitoring patient response to treatment of retinal oxidative diseases
JP2023141229A (ja) 高リン血症治療用医薬用組成物
WO1999004783A1 (en) Composition for protection from damage by ischemia
JPH1192384A (ja) 腫瘍治療に使用するための医薬組成物
JPH0480007B2 (enExample)
EA043008B1 (ru) Комбинации эдаравона для лечения ишемических повреждений мозга
US20220031690A1 (en) Anti-neurodegenerative disease agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051461

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250826

Address after: St Gallen

Applicant after: Weifu (International) Co.,Ltd.

Country or region after: Switzerland

Address before: Palma, Mallorca, Balearic Islands, Spain

Applicant before: Sanifeld treatment Co.,Ltd.

Country or region before: Spain